(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Rocket Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast RCKT's revenue for 2025 to be $1,488,938,041, with the lowest RCKT revenue forecast at $1,488,938,041, and the highest RCKT revenue forecast at $1,488,938,041. On average, 4 Wall Street analysts forecast RCKT's revenue for 2026 to be $13,669,571,687, with the lowest RCKT revenue forecast at $399,707,679, and the highest RCKT revenue forecast at $28,011,858,940.
In 2027, RCKT is forecast to generate $9,975,022,969 in revenue, with the lowest revenue forecast at $2,708,531,284 and the highest revenue forecast at $17,241,622,391.